Almorexant (INN), also known by its development code ACT-078573, is an orexin antagonist, acting as a competitive antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to concerns over the hepatic safety of almorexant after transient increases in liver enzymes were observed in trials.
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 477318417 | IUPAC_name = (2R)-2-[(1S)- 6,7-Dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylacetamide | image = Almorexant.svg | image_class = skin-invert-image | width = 200px
| tradename = | routes_of_administration = By mouth | class = Orexin antagonist
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).